Back to Whitepaper Library
WhitepaperVitamins

How Centrum Can Defend and Grow AI Visibility in Multivitamins

Centrum leads AI recommendations in multivitamins with 24.7% share — but the lead is uneven across AI platforms. This Haleon whitepaper maps how to defend and grow it.

15 min read·AgentRank by Consensys·June 1, 2026
24.7%
Centrum's global AI recommendation share in multivitamins

Multivitamins is a leader-dominated AI category

Across ChatGPT, Claude, Gemini, Grok and Deepseek, multivitamins is one of the most concentrated AI recommendation categories tracked. Centrum holds 24.7% of brand recommendation share — roughly three times its nearest rival, One A Day at 8.2%, followed by Blackmores (5.4%), Supradyn (4.9%) and Nature Made (4.4%).

At a manufacturer level, Haleon leads the category at 25.1% share, a 9.9-point lead over Bayer. Crucially, that position is almost entirely Centrum-led: Centrum is classified 'Defend' while Multicentrum is 'Review'. The strategy is one brand, one focus — protect and strengthen Centrum's recommendation authority rather than spreading investment.

The core risk: uneven across AI platforms

Centrum's biggest vulnerability is not share — it is platform variance. There is a 59-point spread between its strongest and weakest platform. Centrum is strongest where AI rewards mainstream wellness language (Grok index 125, ChatGPT 115, Gemini 104) and weakest where AI demands ingredient-level proof (Claude 90, Deepseek 66).

Closing the gap is a proof problem, not an awareness problem. Platforms like Deepseek and Claude need stronger technical evidence — bioavailability, ingredient forms, mineral chelates, dietary specificity and third-party testing — to keep recommending Centrum with confidence.

  • Grok 125 · ChatGPT 115 · Gemini 104 — reward mainstream wellness language
  • Claude 90 · Deepseek 66 — demand ingredient-level technical proof
  • Deepseek is the #1 global platform fix

Asia is three different Centrum realities

Centrum's Asian footprint splits into three strategic clusters. Defend leadership in Taiwan (33%), Philippines (32%), Malaysia (31%), Thailand (29%), China (23%) and South Korea (20.4%). Accelerate growth in Vietnam, Indonesia and India, where gaps to the leader are a narrow 3.6–6.4pp. Treat Japan (7%, a 26pp gap) as selective, segment-specific expansion only.

  • Defend: Taiwan, Philippines, Malaysia, Thailand, China, South Korea
  • Accelerate: Vietnam, Indonesia, India — narrowest gaps, highest upside
  • Selective: Japan — structurally weak, senior/nutrient-gap segments only

The phrases AI needs to repeat about Centrum

AI recommendations use direct, consumer-facing language. Centrum should engineer content so winning phrases appear consistently across PDPs, FAQs, pharmacy pages and reviews — while closing the negative drivers that cause technical platforms to hedge.

  • Completeness — 'complete daily nutrition', 'fills nutrient gaps'
  • Energy & immunity — 'supports immunity', 'helps reduce tiredness'
  • Absorption — 'bioavailable forms', 'certified high absorption'
  • Verification — 'third-party tested', 'USP verified', 'non-GMO'
  • Fix negatives: methylated B12/folate, mineral chelate detail, bioavailability proof

Five moves to stay #1

  • Own the mainstream daily wellness answer on every platform
  • Add technical proof underneath without losing simplicity
  • Fix Deepseek as the #1 platform priority
  • Execute the Asia cluster strategy (defend / accelerate / selective)
  • Stretch into adjacent segments only where proof aligns (mineral supplements first)

Key takeaways

  • Centrum leads multivitamins AI recommendations at 24.7% share, 3x its nearest rival.
  • The real risk is a 59-point platform variance, not overall share.
  • Deepseek and Claude need ingredient-level proof to recommend Centrum confidently.
  • Asia splits into defend, accelerate and selective-expansion clusters.

Frequently asked questions

Why is Centrum's AI visibility uneven across platforms?

Platforms like Grok and ChatGPT reward mainstream wellness language, where Centrum is strong, while Claude and Deepseek demand ingredient-level proof such as bioavailability and methylated forms, where Centrum is weaker.

What is the single biggest priority for Centrum?

Fixing Deepseek — its weakest platform at an index of 66 — by adding ingredient specificity, methylated forms, mineral chelates, review quality and value-for-money framing.

Get the full report

Download this whitepaper as a PDF.